{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:31:19Z","timestamp":1793082679154,"version":"4.5.0"},"reference-count":79,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>In recent years, there has been increasing evidence that several lipid metabolism abnormalities play an important role in the pathogenesis of neurodegenerative diseases. However, it is still unclear which lipid metabolism abnormalities play the most important role in neurodegenerative diseases. Plasma lipid metabolomics (lipidomics) has been shown to be an unbiased method that can be used to explore lipid metabolism abnormalities in neurodegenerative diseases. Plasma lipidomics in neurodegenerative diseases has been performed only in idiopathic Parkinson\u2019s disease (IPD) and Alzheimer\u2019s disease (AD), and comprehensive studies are needed to clarify the pathogenesis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>In this study, we investigated plasma lipids using lipidomics in individuals with neurodegenerative diseases and healthy controls (CNs). Plasma lipidomics was evaluated by liquid chromatography-tandem mass spectrometry (LC\u2013MS\/MS) in those with IPD, dementia with Lewy bodies (DLB), multiple system atrophy (MSA), AD, and progressive supranuclear palsy (PSP) and CNs.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The results showed that (1) plasma sphingosine-1-phosphate (S1P) was significantly lower in all neurodegenerative disease groups (IPD, DLB, MSA, AD, and PSP) than in the CN group. (2) Plasma monohexylceramide (MonCer) and lactosylceramide (LacCer) were significantly higher in all neurodegenerative disease groups (IPD, DLB, MSA, AD, and PSP) than in the CN group. (3) Plasma MonCer levels were significantly positively correlated with plasma LacCer levels in all enrolled groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>S1P, Glucosylceramide (GlcCer), the main component of MonCer, and LacCer are sphingolipids that are biosynthesized from ceramide. Recent studies have suggested that elevated GlcCer and decreased S1P levels in neurons are related to neuronal cell death and that elevated LacCer levels induce neurodegeneration by neuroinflammation. In the present study, we found decreased plasma S1P levels and elevated plasma MonCer and LacCer levels in those with neurodegenerative diseases, which is a new finding indicating the importance of abnormal sphingolipid metabolism in neurodegeneration.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0279315","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T18:25:07Z","timestamp":1671215107000},"page":"e0279315","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":29,"title":["Plasma sphingolipid abnormalities in neurodegenerative diseases"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2856-4233","authenticated-orcid":true,"given":"Hideki","family":"Oizumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Sugimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Totsune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iori","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Ohshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teiko","family":"Kimpara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-7847","authenticated-orcid":true,"given":"Ichiro","family":"Kawahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-2486","authenticated-orcid":true,"given":"Atsushi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"key":"pone.0279315.ref001","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"5","author":"LML de Lau","year":"2006","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"pone.0279315.ref002","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1017\/cjn.2016.2","article-title":"The prevalence and incidence of dementia with lewy bodies: a systematic review","volume":"43","author":"DB Hogan","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"pone.0279315.ref003","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease","volume":"51","author":"WR Gibb","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"pone.0279315.ref004","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with lewy bodies","volume":"95","author":"MG Spillantini","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0279315.ref005","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"S Gilman","year":"2008","journal-title":"Neurology"},{"key":"pone.0279315.ref006","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0304-3940(98)00407-8","article-title":"Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy","volume":"249","author":"K Wakabayashi","year":"1998","journal-title":"Neurosci Lett"},{"key":"pone.0279315.ref007","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1440-1789.2006.00713.x","article-title":"Cellular pathology in multiple system atrophy","volume":"26","author":"K Wakabayashi","year":"2006","journal-title":"Neuropathology"},{"key":"pone.0279315.ref008","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S1353-8020(13)70017-8","article-title":"\u03b1-Synucleinopathy phenotypes","volume":"20","author":"H McCann","year":"2014","journal-title":"Park Relat Disord"},{"key":"pone.0279315.ref009","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","article-title":"The global prevalence of dementia: a systematic review and metaanalysis","volume":"9","author":"M Prince","year":"2013","journal-title":"Alzheimers Dement"},{"key":"pone.0279315.ref010","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/ncb1104-1054","article-title":"Cell biology of protein misfolding: the examples of Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"6","author":"DJ Selkoe","year":"2004","journal-title":"Nat Cell Biol"},{"key":"pone.0279315.ref011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","article-title":"Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop","volume":"47","author":"I Litvan","year":"1996","journal-title":"Neurology"},{"key":"pone.0279315.ref012","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","article-title":"Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches","volume":"16","author":"AL Boxer","year":"2017","journal-title":"Lancet Neurol"},{"key":"pone.0279315.ref013","doi-asserted-by":"crossref","first-page":"101644","DOI":"10.1016\/j.pneurobio.2019.101644","article-title":"Four-repeat tauopathies","volume":"180","author":"TW Rosler","year":"2019","journal-title":"Prog Neurobiol"},{"key":"pone.0279315.ref014","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pneurobio.2015.07.003","article-title":"Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies","volume":"155","author":"M Bourdenx","year":"2017","journal-title":"Prog Neurobiol"},{"key":"pone.0279315.ref015","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","article-title":"Roles of tau protein in health and disease","volume":"133","author":"T Guo","year":"2017","journal-title":"Acta Neuropathol"},{"key":"pone.0279315.ref016","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2174\/157015911798376181","article-title":"Alzheimer\u2019s disease: pathological mechanisms and recent insights","volume":"9","author":"DM Niedowicz","year":"2011","journal-title":"Curr Neuropharmacol"},{"key":"pone.0279315.ref017","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/cells8010027","article-title":"The Role of Lipids in Parkinson\u2019s Disease","volume":"8","author":"H Xicoy","year":"2019","journal-title":"Cells"},{"key":"pone.0279315.ref018","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1212\/WNL.0000000000003663","article-title":"Metabolomic biomarkers as strong correlates of Parkinson disease progression","volume":"88","author":"PA LeWitt","year":"2017","journal-title":"Neurology"},{"key":"pone.0279315.ref019","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3233\/JAD-142319","article-title":"Sphingomyelin SM(d18:1\/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-beta42, tau, and phospho-tau-181 levels","volume":"44","author":"T Koal","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"pone.0279315.ref020","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.nbd.2009.02.019","article-title":"Metabolomics tools for identifying biomarkers for neuropsychiatric diseases","volume":"35","author":"MP Quinones","year":"2009","journal-title":"Neurobiol Dis"},{"key":"pone.0279315.ref021","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.12659\/MSM.904399","article-title":"High Performance Liquid Chromatography-Mass Spectrometry (LC-MS) Based Quantitative Lipidomics Study of Ganglioside-NANA-3 Plasma to Establish Its Association with Parkinson\u2019s Disease Patients","volume":"23","author":"J Zhang","year":"2017","journal-title":"Med Sci Monit"},{"key":"pone.0279315.ref022","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41398-021-01362-2","article-title":"Plasma lipidome is dysregulated in Alzheimer\u2019s disease and is associated with disease risk genes","volume":"11","author":"Y Liu","year":"2021","journal-title":"Transl Psychiatry"},{"key":"pone.0279315.ref023","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"GM McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"pone.0279315.ref024","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria","volume":"32","author":"GU Hoglinger","year":"2017","journal-title":"Mov Disord"},{"key":"pone.0279315.ref025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"IG McKeith","year":"2017","journal-title":"Neurology"},{"key":"pone.0279315.ref026","doi-asserted-by":"crossref","first-page":"7328","DOI":"10.1038\/s41598-017-06767-y","article-title":"Decreased long-chain acylcarnitines from insufficient beta-oxidation as potential early diagnostic markers for Parkinson\u2019s disease","volume":"7","author":"S Saiki","year":"2017","journal-title":"Sci Rep"},{"key":"pone.0279315.ref027","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11040215","article-title":"Metabolomic Analysis of Small Extracellular Vesicles Derived from Pancreatic Cancer Cells Cultured under Normoxia and Hypoxia","volume":"11","author":"R Hayasaka","year":"2021","journal-title":"Metabolites"},{"key":"pone.0279315.ref028","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12060566","article-title":"Comparative Metabolomics of Small Molecules Specifically Expressed in the Dorsal or Ventral Marginal Zones in Vertebrate Gastrula","volume":"12","author":"Y Suzuki","year":"2022","journal-title":"Metabolites"},{"key":"pone.0279315.ref029","first-page":"349","author":"K. Ikeda","year":"2015","journal-title":"Mass Spectrometric Analysis of Phospholipids by Target Discovery Approach"},{"key":"pone.0279315.ref030","doi-asserted-by":"crossref","first-page":"e0223113","DOI":"10.1371\/journal.pone.0223113","article-title":"Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy","volume":"14","author":"A Mori","year":"2019","journal-title":"PLoS One"},{"key":"pone.0279315.ref031","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ana.25516","article-title":"A metabolic profile of polyamines in parkinson disease: A promising biomarker","volume":"86","author":"S Saiki","year":"2019","journal-title":"Ann Neurol"},{"key":"pone.0279315.ref032","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease","volume":"361","author":"E Sidransky","year":"2009","journal-title":"N Engl J Med"},{"key":"pone.0279315.ref033","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/hmg\/ddq454","article-title":"Large-scale screening of the Gaucher\u2019s disease-related glucocerebrosidase gene in Europeans with Parkinson\u2019s disease","volume":"20","author":"S Lesage","year":"2011","journal-title":"Hum Mol Genet"},{"key":"pone.0279315.ref034","first-page":"2890 e2813","article-title":"Rare lysosomal enzyme gene SMPD1 variant (p.R591C) associates with Parkinson\u2019s disease","volume":"34","author":"JN Foo","year":"2013","journal-title":"Neurobiol Aging"},{"key":"pone.0279315.ref035","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jns.2013.08.033","article-title":"Parkinsonism syndrome in heterozygotes for Niemann-Pick C1","volume":"335","author":"HH Kluenemann","year":"2013","journal-title":"J Neurol Sci"},{"key":"pone.0279315.ref036","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1212\/01.wnl.0000327094.67726.28","article-title":"Neurodegeneration associated with genetic defects in phospholipase A(2)","volume":"71","author":"A Gregory","year":"2008","journal-title":"Neurology"},{"key":"pone.0279315.ref037","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/hmg\/3.4.569","article-title":"Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer\u2019s disease: analysis of the 19q13.2 chromosomal region","volume":"3","author":"MC Chartier-Harlin","year":"1994","journal-title":"Hum Mol Genet"},{"key":"pone.0279315.ref038","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1074\/jbc.M009598200","article-title":"Accumulation and aggregation of amyloid beta-protein in late endosomes of Niemann-pick type C cells","volume":"276","author":"T Yamazaki","year":"2001","journal-title":"J Biol Chem"},{"key":"pone.0279315.ref039","article-title":"Lipid metabolism and Alzheimer\u2019s disease: clinical evidence, mechanistic link and therapeutic promise","author":"F. Yin","year":"2022","journal-title":"FEBS J"},{"key":"pone.0279315.ref040","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1194\/jlr.D089797","article-title":"DMS as an orthogonal separation to LC\/ESI\/MS\/MS for quantifying isomeric cerebrosides in plasma and cerebrospinal fluid","volume":"60","author":"H Xu","year":"2019","journal-title":"J Lipid Res"},{"key":"pone.0279315.ref041","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nature13475","article-title":"Sphingolipid metabolites in inflammatory disease","volume":"510","author":"M Maceyka","year":"2014","journal-title":"Nature"},{"key":"pone.0279315.ref042","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1007\/s12035-018-1286-3","article-title":"The Cross-Talk Between Sphingolipids and Insulin-Like Growth Factor Signaling: Significance for Aging and Neurodegeneration","volume":"56","author":"H Jesko","year":"2019","journal-title":"Mol Neurobiol"},{"key":"pone.0279315.ref043","doi-asserted-by":"crossref","first-page":"13639","DOI":"10.1038\/s41598-018-31756-0","article-title":"Particular CSF sphingolipid patterns identify iNPH and AD patients","volume":"8","author":"E Torretta","year":"2018","journal-title":"Sci Rep"},{"key":"pone.0279315.ref044","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13195-020-00694-3","article-title":"Immunomodulatory sphingosine-1-phosphates as plasma biomarkers of Alzheimer\u2019s disease and vascular cognitive impairment","volume":"12","author":"XY Chua","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"pone.0279315.ref045","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.pharep.2018.05.002","article-title":"Sphingosine kinase 1\/sphingosine-1-phosphate receptors dependent signalling in neurodegenerative diseases. The promising target for neuroprotection in Parkinson\u2019s disease","volume":"70","author":"J Motyl","year":"2018","journal-title":"Pharmacol Rep"},{"key":"pone.0279315.ref046","doi-asserted-by":"crossref","first-page":"113120","DOI":"10.1016\/j.expneurol.2019.113120","article-title":"FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in Multiple System Atrophy mouse models","volume":"325","author":"G Vidal-Martinez","year":"2020","journal-title":"Exp Neurol"},{"key":"pone.0279315.ref047","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.1074\/jbc.RA118.001986","article-title":"Extracellular alpha-synuclein drives sphingosine 1-phosphate receptor subtype 1 out of lipid rafts, leading to impaired inhibitory G-protein signaling","volume":"293","author":"SMM Badawy","year":"2018","journal-title":"J Biol Chem"},{"key":"pone.0279315.ref048","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2051-5960-2-9","article-title":"Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer\u2019s disease pathogenesis","volume":"2","author":"TA Couttas","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"pone.0279315.ref049","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s12031-013-9979-6","article-title":"FTY720 (fingolimod) attenuates beta-amyloid peptide (Abeta42)-induced impairment of spatial learning and memory in rats","volume":"50","author":"M Asle-Rousta","year":"2013","journal-title":"J Mol Neurosci"},{"key":"pone.0279315.ref050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.brainres.2017.01.014","article-title":"The sphingosine-1-phosphate receptor 1 agonist SEW2871 reduces Tau-Ser262 phosphorylation in rat hippocampal slices","volume":"1658","author":"F St-Cyr Giguere","year":"2017","journal-title":"Brain Res"},{"key":"pone.0279315.ref051","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.dadm.2016.02.005","article-title":"Plasma sphingolipid changes with autopsy-confirmed Lewy Body or Alzheimer\u2019s pathology","volume":"3","author":"R Savica","year":"2016","journal-title":"Alzheimers Dement (Amst)"},{"key":"pone.0279315.ref052","doi-asserted-by":"crossref","first-page":"e73094","DOI":"10.1371\/journal.pone.0073094","article-title":"Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson\u2019s disease and associated with cognitive impairment: a pilot study","volume":"8","author":"MM Mielke","year":"2013","journal-title":"PLoS One"},{"key":"pone.0279315.ref053","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/mds.20319","article-title":"Analysis of the glucocerebrosidase gene in Parkinson\u2019s disease","volume":"20","author":"C Sato","year":"2005","journal-title":"Mov Disord"},{"key":"pone.0279315.ref054","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","article-title":"A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies","volume":"70","author":"MA Nalls","year":"2013","journal-title":"JAMA Neurol"},{"key":"pone.0279315.ref055","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/ijms18020441","article-title":"A review of gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"J Stirnemann","year":"2017","journal-title":"Int J Mol Sci"},{"key":"pone.0279315.ref056","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.parkreldis.2017.08.026","article-title":"Serum lipid alterations in GBA-associated Parkinson\u2019s disease","volume":"44","author":"LC Guedes","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"key":"pone.0279315.ref057","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"JR Mazzulli","year":"2011","journal-title":"Cell"},{"key":"pone.0279315.ref058","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.22400","article-title":"Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing","volume":"69","author":"V Cullen","year":"2011","journal-title":"Ann Neurol"},{"key":"pone.0279315.ref059","doi-asserted-by":"crossref","first-page":"28080","DOI":"10.1074\/jbc.M111.237859","article-title":"Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases","volume":"286","author":"TL Yap","year":"2011","journal-title":"J Biol Chem"},{"key":"pone.0279315.ref060","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1093\/hmg\/ddw185","article-title":"Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease","volume":"25","author":"J Magalhaes","year":"2016","journal-title":"Hum Mol Genet"},{"key":"pone.0279315.ref061","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/brain\/awt367","article-title":"Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson\u2019s disease","volume":"137","author":"KE Murphy","year":"2014","journal-title":"Brain"},{"key":"pone.0279315.ref062","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000362987","article-title":"PS dependent APP cleavage regulates glucosylceramide synthase and is affected in Alzheimer\u2019s disease","volume":"34","author":"MO Grimm","year":"2014","journal-title":"Cell Physiol Biochem"},{"key":"pone.0279315.ref063","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1074\/jbc.M111.274142","article-title":"Comparative lipidomic analysis of mouse and human brain with Alzheimer disease","volume":"287","author":"RB Chan","year":"2012","journal-title":"J Biol Chem"},{"key":"pone.0279315.ref064","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3390\/ijms22041816","article-title":"Convergence: lactosylceramide-centric signaling pathways induce inflammation, oxidative stress, and other phenotypic outcomes","volume":"22","author":"S Chatterjee","year":"2021","journal-title":"Int J Mol Sci"},{"key":"pone.0279315.ref065","doi-asserted-by":"crossref","first-page":"691230","DOI":"10.3389\/fnagi.2021.691230","article-title":"The Involvement of Lactosylceramide in Central Nervous System Inflammation Related to Neurodegenerative Disease","volume":"13","author":"W Yu","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"pone.0279315.ref066","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1021\/cr2002917","article-title":"Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics","volume":"111","author":"AH Merrill","year":"2011","journal-title":"Chem Rev"},{"key":"pone.0279315.ref067","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/tra.12239","article-title":"Sphingolipid metabolism and interorganellar transport: localization of sphingolipid enzymes and lipid transfer proteins","volume":"16","author":"T Yamaji","year":"2015","journal-title":"Traffic"},{"key":"pone.0279315.ref068","doi-asserted-by":"crossref","first-page":"e0172348","DOI":"10.1371\/journal.pone.0172348","article-title":"Elevated GM3 plasma concentration in idiopathic Parkinson\u2019s disease: A lipidomic analysis","volume":"12","author":"RB Chan","year":"2017","journal-title":"PLoS One"},{"key":"pone.0279315.ref069","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1096\/fj.05-4911fje","article-title":"Ganglioside GM3 is involved in neuronal cell death","volume":"20","author":"H Sohn","year":"2006","journal-title":"FASEB J"},{"key":"pone.0279315.ref070","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1126\/science.277.5332.1652","article-title":"Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis","volume":"277","author":"R De Maria","year":"1997","journal-title":"Science"},{"key":"pone.0279315.ref071","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.brainresbull.2010.02.013","article-title":"Lipid rafts: keys to neurodegeneration","volume":"82","author":"CL Schengrund","year":"2010","journal-title":"Brain Res Bull"},{"key":"pone.0279315.ref072","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1007\/s11064-011-0437-y","article-title":"Mice lacking major brain gangliosides develop parkinsonism","volume":"36","author":"G Wu","year":"2011","journal-title":"Neurochem Res"},{"key":"pone.0279315.ref073","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1242\/jcs.02637","article-title":"Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling","volume":"118","author":"CE Chalfant","year":"2005","journal-title":"J Cell Sci"},{"key":"pone.0279315.ref074","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1476-511X-9-15","article-title":"Ceramide and ceramide 1-phosphate in health and disease","volume":"9","author":"L Arana","year":"2010","journal-title":"Lipids Health Dis"},{"key":"pone.0279315.ref075","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","article-title":"Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?","volume":"17","author":"F Leng","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"pone.0279315.ref076","doi-asserted-by":"crossref","first-page":"4784268","DOI":"10.1155\/2018\/4784268","article-title":"Linking Neuroinflammation and Neurodegeneration in Parkinson\u2019s Disease","volume":"2018","author":"G Gelders","year":"2018","journal-title":"J Immunol Res"},{"key":"pone.0279315.ref077","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.parkreldis.2015.10.009","article-title":"Neuroinflammation in Lewy body dementia","volume":"21","author":"A Surendranathan","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"pone.0279315.ref078","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/jnnp.2006.105940","article-title":"Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese","volume":"78","author":"YR Wu","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"pone.0279315.ref079","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41531-021-00241-3","article-title":"Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson\u2019s disease enrolled in PPMI","volume":"7","author":"YE Huh","year":"2021","journal-title":"NPJ Parkinsons Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0279315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T18:26:04Z","timestamp":1671215164000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0279315"}},"subtitle":[],"editor":[{"given":"Stephan N.","family":"Witt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":79,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0279315","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]}}}